MilliporeSigma will now be the first company to make acoustic technology available for cell therapy manufacturing.

The new device protects children from accidentally taking painkillers, antidepressants, or medical cannabis with a new opening mechanism.

The company will present its solutions to reduce procurement costs for customers and help them bring their products to market faster.

The acquisition comes after Bormioli became an independent company owned by Triton Investment Fund in December 2017.

The new facility raises production capacity by an additional 19,100 m2 and creates 200 new full-time jobs.

The increased capacity will enable the company to guarantee short production timelines.

The collaboration focuses on baculovirus/Sf9 expression system for Prevail's pipeline of novel AAV9-based gene therapy programs neurodegenerative diseases.

The new services provide rapid production of antibody drug conjugates (ADCs) for best candidate selection.

Under a collaboration potentially worth more than $1.5 billion, the companies aim to develop the antisense therapy to treat patients with certain cardiovascular and metabolic diseases.

Data from BIA and Informa Pharma Intelligence have shown that, despite investment slowing across all sectors, the biotech sector of the UK is still managing to raise significant funds.

Glenmark Pharmaceuticals has been granted marketing approval from the Russian Ministry of Healthcare for its film-coated tablets, Montlezir, to treat seasonal and perennial allergic rhinitis.

GSK invested $139 million to its Rockville, MD site to support demand for Benlysta.

The agency has approved Gilead Sciences’ Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg) for reducing the risk of HIV-1 infection.

The tables can be used for new drug applications, biologics license applications, and supplements to these applications.

The companies are working together with Japanese clients to outline projects from early clinical stage up to commercial launch.

The new joint venture, named Oerth Bio, will use Arvinas’ Protac technology to develop innovative new agricultural products. As part of its collaboration with Arvinas, Bayer is also using this technology to develop human therapeutics.

The contraceptive is expected to receive new chemical entity designation from FDA, giving it patent protection beyond 2030. It will be launched in early 2021, pending FDA approval.

Manufacturing of the cell line will take place at Lonza’s GMP facility in Geleen, Netherlands.

The companies agreed to a multi-year research and development collaboration that will focus on AI empowerment and exploration.

Data showed that the drug candidate activated T regulatory cells, believed to serve a crucial role in protecting the body from uncontrolled inflammation or autoimmunity.

The root cause of NDMA contamination may go well beyond manufacturing problems, to the molecule itself.

The new incubators are set to be operational starting in 2021.

Researchers used advanced animal model lab tests to determine the new vector is 10 times more efficient at incorporating corrective genes into bone marrow stem cells than traditional vectors.

The agency seeks comments on a draft guidance designed to make the process conform to its original intent as a communication tool, rather than a roadblock to competition and innovation.

FDA and DEA warn four website operators to stop illegally selling opioids.

Climbing out of a reputation hole starts with adopting a quality culture.

With no plausibly approvable deal on the table in the UK government at the moment, it is possible that Brexit could be extended even further.

A new European Commission is likely, with the support of a new European Parliament, to give a higher profile to healthcare and pharmaceutical matters during its five years in office.